TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

DSpace/Manakin Repository

TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

Citable link to this page

 

 
Title: TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Author: Sakuishi, Kaori; Ngiow, Shin Foong; Sullivan, Jenna M.; Teng, Michele W. L.; Kuchroo, Vijay K.; Smyth, Mark J.; Anderson, Ana C.

Note: Order does not necessarily reflect citation order of authors.

Citation: Sakuishi, Kaori, Shin Foong Ngiow, Jenna M. Sullivan, Michele W. L. Teng, Vijay K. Kuchroo, Mark J. Smyth, and Ana C. Anderson. 2013. “TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer.” Oncoimmunology 2 (4): e23849. doi:10.4161/onci.23849. http://dx.doi.org/10.4161/onci.23849.
Full Text & Related Files:
Abstract: T-cell immunoglobulin mucin 3 (TIM3) is an inhibitory molecule that has emerged as a key regulator of dysfunctional or exhausted CD8+ T cells arising in chronic diseases such as cancer. In addition to exhausted CD8+ T cells, highly suppressive regulatory T cells (Tregs) represent a significant barrier against the induction of antitumor immunity. We have found that the majority of intratumoral FOXP3+ Tregs express TIM3. TIM3+ Tregs co-express PD-1, are highly suppressive and comprise a specialized subset of tissue Tregs that are rarely observed in the peripheral tissues or blood of tumor-bearing mice. The co-blockade of the TIM3 and PD-1 signaling pathways in vivo results in the downregulation of molecules associated with TIM3+ Treg suppressor functions. This suggests that the potent clinical efficacy of co-blocking TIM3 and PD-1 signal transduction cascades likely stems from the reversal of T-cell exhaustion combined with the inhibition of regulatory T-cell function in tumor tissues. Interestingly, we find that TIM3+ Tregs accumulate in the tumor tissue prior to the appearance of exhausted CD8+ T cells, and that the depletion of Tregs at this stage interferes with the development of the exhausted phenotype by CD8+ T cells. Collectively, our data indicate that TIM3 marks highly suppressive tissue-resident Tregs that play an important role in shaping the antitumor immune response in situ, increasing the value of TIM3-targeting therapeutic strategies against cancer.
Published Version: doi:10.4161/onci.23849
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654601/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11708647
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters